A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis

← catalyst calendar

NCT06526182 · readout in 249 d

Sponsored by Almirall, S.A. (industry) · ALM.MC — their whole pipeline →.

Phase

Phase 3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

520estimated

Sites

Country

Spain

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-07-03

actual

When the study began enrolling

Primary completion

2027-04-25

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-04-25

estimated

The whole study's end, after follow-up

First posted

2024-07-29

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-04-21

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

Dermatitis, Atopic
Eczema

Interventions

Biological: Lebrikizumab
Other: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Part 1: Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Score Less than or Equal to (<=) 7 at Week 24

measured At Week 24

Part 2: Percentage of Participants Achieving EASI 75 at Week 36

measured At Week 36

Part 2: Percentage of Participants with an IGA Score of 0 or 1 and a Reduction >=2 Points

measured From Baseline (Part 1) up to Week 36

Permalink · ALM.MC's whole pipeline · Catalyst calendar · Every registered study · What changed